21st Sep 2021 06:31
Arecor Therapeutics PLC - Cambridge, England-based biotechnology company - Says its ultra-concentrated ultra-rapid acting insulin, AT278, met all of its primary and secondary endpoints with positive headline results from the phase I clinical trial.
"AT278 has the potential to disrupt the market for insulin treatment in people with diabetes, as the first concentrated, yet rapid acting, insulin - a critical enabler in the development of next generation miniaturised insulin delivery systems," says Chief Executive Sarah Howell.
Current stock price: 329.75 pence
Change since June 4: up 36%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Arecor Therape